Home » Topics » BioWorld Science

BioWorld Science
RSS

Genmab and Immatics partner on next-generation bispecific cancer immunotherapies

July 12, 2018

New phase II trial explores voclosporin ophthalmic solution for dry eye syndrome

July 12, 2018

Pivotal study of KP-415 in children with ADHD meets primary efficacy endpoint

July 12, 2018

Galapagos, AbbVie discover CFTR modulators

July 12, 2018

National Center for Global Health and Medicine, Kumamoto University and Yamasa patent antivirals

July 12, 2018

Amgen describes new beta-secretase inhibitors

July 12, 2018

OG-716, a lantibiotic that is active against Clostridium difficile infections

July 12, 2018

Argenx presents phase II data for ARGX-113 in myasthenia gravis

July 12, 2018

Advaxis withdraws conditional MAA for axalimogene filolisbac, advances ADXS-HOT program

July 12, 2018

Recursion set to begin phase I study of AI/ML-based drug candidate, REC-994

July 12, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...